Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients

American Journal of Cardiovascular Drugs

Volumn 11, Issue 6, 2011, Pages 383-394

  Fisher, Stacy D ^a   Kanda, Brinder S ^b   Miller, Tracie L ^c   Lipshultz, Steven E ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretrovirals; Atherosclerosis; Cardiomyopathies; Cardiovascular disorders; HIV 1 infections; Pericardial effusion

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; FOSCARNET; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; BARE METAL STENT; BODY MASS; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPLETE HEART BLOCK; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG EXPOSURE; DYSAUTONOMIA; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; EXERCISE; FETUS DISEASE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RIGHT VENTRICLE FAILURE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOLTER MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INTRAVENOUS DRUG ABUSE; KAPOSI SARCOMA; LIPID BLOOD LEVEL; LIPID METABOLISM; MYOCARDITIS; MYOPATHY; NUTRITIONAL DEFICIENCY; PERICARDIAL EFFUSION; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; POLYMORPHIC VENTRICULAR TACHYCARDIA; PR INTERVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TORSADE DES POINTES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE;

EID: 83155189921     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11594590-000000000-00000     Document Type: Article

References (61)

1. Editorial. Tackling cancer and heart disease in people with HIV/AIDS. Lancet 2011; 377: 1380
2. UNAIDS global report. UN report on the Global AIDS epidemic 2010 [online]. Available from URL: http://www.unaids.org/globalreport/global- report.htm [Accessed 2011 Sep 1]
3. McKinney Jr RE. Shooting at a moving target: natural history studies and the rapidly improving state of anti-HIV treatment. J Pediatr 2002; 141(3): 301-2
4. Fisher SD, Lipshultz SE. Chapter 72: Cardiovascular abnormalities in HIVinfected individuals. In: Bonow RO, Mann DL, Zipes DP, et al., editors. Braunwald's heart disease: A textbook of cardiovascular medicine. 9th ed. Philadelphia (PA): Elsevier Saunders, 2011: 1618-27
5. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIVinfected adults. N Engl J Med 2005; 352: 48-62 (Pubitemid 40075680)
6. Mu H, Chai H, Lin PH, et al. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31 (4): 632-43 (Pubitemid 46496230)
7. Voelker R. Stroke increase reported in HIV patients. JAMA 2011; 9: 305 (6): 552
8. Boccara F, Teiger E, Cohen A, et al. Percutaneous coronary intervention in HIV infected patients: Immediate results and long term prognosis. Heart 2006; 92: 543-4
9. Ren X, Trilesskaya M, Kwan DM, et al. Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection. Am J Cardiol 2009 15; 104 (2): 216-22
10. DAD study group investigators. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22 (14): F17-24
11. Ding X, Andraca-Carrera E, Cooper C. No association of myocardial infarction with ABC use: An FDA meta-analysis [abstract no. 808]. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston (MA), Feb/Mar 2011 [online]. Available from URL: http://www.retroconfer ence.org/2011/Abstracts/42436.htm [Accessed 2011 Oct 17]
12. Zapor MJ, Cozza KL, Wynn GH, et al. Antiretrovirals. Part II: Focus on nonprotease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 2004; 45 (6): 524-35 (Pubitemid 41071374)
13. Fillipas S, Cherry CL, Cicuttini F, et al. The effects of exercise training on metabolic and morphological outcomes for people living with HIV: A systematic review of randomised controlled trials. HIV Clin Trials 2010; 11 (5): 270-82
14. Divi RL, Leonard SL, Kuo MM, et al. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 2005; 5 (3): 333-46 (Pubitemid 41506873)
15. ViganòA, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther 2005; 10 (8): 917-24 (Pubitemid 43076343)
16. Randell PA, Jackson AG, Zhong L. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther 2010; 15 (2): 227-33
17. Portilla J. Safety and tolerability of etravirine [in Spanish]. Enferm Infecc Microbiol Clin 2009; 27 (Suppl. 2): 21-6
18. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. NEJM 2007; 356: 1723-35
19. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (DAD) study. J Infect Dis 2010; 201 (3): 318-30
20. Soliman EZ, Lundgren JD, Roediger MP, et al., for the INSIGHT SMART study group. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25 (3): 367-7
21. Zhang X, Jordan P, Cristea L, et al. Thorough QT/QTc study of ritonavirboosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. J Clin Pharmacol 2011 May 10. Epub ahead of print
22. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: A Danish nationwide populationbased cohort study. AIDS 2011 Jun 3. Epub ahead of print
23. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D study. HIV Med 2011. Epub ahead of print. doi: 10.1111/j.1468-1293. 2010.00901.x
24. Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: A cohort and nested case-control study using Québec's public health insurance database (RAMQ). J Acquir Immune Defic Syndr 2011. Epub ahead of print
25. Maggi P, Bellacosa C, Carito V, et al. Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. J Antimicrob Chemother 2011; 66 (4): 896-900
26. Lipshultz SE, Fisher SD, Lai WW, et al. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 2003; 17: S96-122 (Pubitemid 36667787)
27. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 49 Suppl. 2: S79-85
28. Carey D, Amin J, Boyd M, et al. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65 (9): 1878-88
29. MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: Results from the MERIT trial. HIV Clin Trials 2011; 12 (1): 24-36
30. Calza L, Manfredi R, Colangeli V, et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6 (6): 572-8
31. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: Exploratory analyses from the SMART trial. Antivir Ther 2008; 13 (2): 177-87 (Pubitemid 351535369)
32. Friis-Møller N, Thiébaut R, Reiss P, et al., DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17 (5): 491-501
33. Aboud M, Elgalib A, Pomeroy L, et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: Implications for clinical management. The CREATE 1 study. Int J Clin Pract 2010; 64 (9): 1252-9
34. Miller TL, Somarriba G, Kinnamon DD, et al. The effect of a structured exercise program on nutrition and fitness outcomes in human immunodeficiency virus-infected children. AIDS Res Hum Retroviruses 2010; 26 (3): 313-9
35. Farinatti PT, Borges JP, Gomes RD, et al. Effects of a supervised exercise program on the physical fitness and immunological function of HIV-infected patients. J Sports Med Phys Fitness 2010; 50 (4): 511-8
36. Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov 2011; 10 (2): 95-6
37. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011 25; 171 (8): 737-43
38. Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 2000; 102: 1542-8
39. Lipshultz SE, Shearer WT, Thompson B, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol 2011 4; 57 (1): 76-85
40. Fisher SD, Bowles NE, Towbin JA, et al. Mediators in HIV-associated cardiovascular disease: A focus on cytokines and genes. AIDS 2003; 17: 29-35
41. Al-Attar I, Orav EJ, Exil V, et al. Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol 2003; 41: 1598-605 (Pubitemid 36543381)
42. Miller TL, Agostoni C, Duggan C, et al. Gastrointestinal and nutritional complications of human immunodeficiency virus infection. J Pediatr Gastroenterol Nutr 2008; 47 (2): 247-53
43. Mondy KE, Gottdiener J, Overton ET, et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Antivir Ther 2009; 14 (8): 1195-208
44. Saidi AS, Moodie DS, Garson Jr A, et al. Electrocardiography and 24-hour electrocardiographic ambulatory recording (Holter monitor) studies in children infected with human immunodeficiency virus type 1. The Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV-1 InfectionStudy Group. Pediatr Cardiol 2000; 21 (3): 189-96 (Pubitemid 30340863)
45. Carillo-Jimenez R, Treadwell TL, Goldfine H, et al. Brain natriuretic peptide and HIV-related cardiomyopathy. AIDS Read 2002; 12 (11): 501-53
46. Schulz-Menger J, Maisch B, Abdel-Aty H, et al. Integrated biomarkers in cardiomyopathies: Cardiovascular magnetic resonance imaging combined with molecular and immunologic markers. A stepwise approach for diagnosis and treatment. Herz 2007; 32 (6): 458-72 (Pubitemid 47468955)
47. Lipshultz SE, Orav EJ, Sanders SP, et al. Immunoglobulins and cardiac structure and function in pediatric HIV infection. Circulation 1995; 92: 2220-5
48. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: The price of success. JAMA 2006; 296: 844-54 (Pubitemid 44223107)
49. Martin-Davila P, Navas E, Fortun J, et al. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: The importance of vegetation size. Am Heart J 2005; 150: 1099-106 (Pubitemid 41607805)
50. Filsoufi F, Salzberg SP, Harbou KT, et al. Excellent outcomes of cardiac surgery in patients infected with HIV in the current era [letter]. Clin Infect Dis 2006; 43: 532
51. Zoufaly A, Stellbrink HJ, Heiden MA. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200 (1): 8-10
52. Bruno R, Sacchi P, Filice G. Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: Impact of highly active antiretroviral therapy [abstract]. AIDS 2003; 17: S83
53. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010 2; 24 (1): 67-75
54. Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2008; 33 (1): 92-8
55. Bermel C, Spüntrup E, Fink G. Stroke in an adult with HIV infection due to carotid artery stenosis successfully treated with steroids: HIV-associated arteritis? J Neurol 2009; 256 (9): 1563-5
56. Guillevin L, Pagnoux C. Therapeutic strategies for systemic necrotizing vasculitides.Allergology Int 2007; 56 (2): 105-11 (Pubitemid 46984238)
57. Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J 2006; 151: 1147-55 (Pubitemid 44172869)
58. Correia D, Rodrigues De, Resende LA, et al. Power spectral analysis of heart rate variability in HIV-infected and AIDS patients. Pacing Clin Electrophysiol 2006; 29: 53-8
59. Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 2005; 97: 1657-61 (Pubitemid 41753112)
60. Nordin C, Kohli A, Beca S, et al. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol 2006; 39: 199-205
61. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58 (RR-11): 1-166